跳至主要内容
临床试验/NCT04019535
NCT04019535已完成不适用

Diastolic Hyperemia Free Index for Assessment of Moderate Coronary Stenoses

Washington University School of Medicine1 个研究点 分布在 1 个国家目标入组 88 人开始时间: 2019年8月22日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
88
试验地点
1
主要终点
Agreement for treatment with iFR

研究概览

简要总结

A total of 106 subjects will be enrolled at up to 3 sites. Initial enrollment will occur at Washington University only. After 15 subjects have been enrolled at the primary site and no serious adverse events or protocol events have occurred the additional sites will be trained and added to enrollment.

详细描述

With the release of DEFINE-FLAIR and iFR SWEDEHEART, coronary physiology and namely iFR, have robust clinical data supporting its routine use in the cardiac catheterization lab. Unfortunately, iFR is a proprietary algorithm owned by Phillips Volcano Corporation (San diego, California, USA) limiting the use of iFR to those centers with Volcano hardware. Whole cardiac cycle Pd/Pa has been another resting measure that has been evaluated and generally performs poorly compared to FFR. Although iFR is measured during the wave free period in diastole, to date there has been no assessment of diastolic Pd/Pa measurements and its potential correlation with the severity of coronary stenoses. Most importantly, evaluating the pressure differential across the entirety of diastole must by definition contain the "iFR value" and therefore should correlate very close with the iFR assessment. Preliminary unpublished data analyzing physiologic data in benchtop modeling from the VERIFY and CONTRAST studies suggest a very high correlation between iFR and diastolic Pd/Pa. This relationship strengthens when measurements are limited to 65% of diastole, hereby named the Diastolic hyperemia-Free Ratio (DFR). These data strongly suggest that DFR could be used as surrogate for iFR when iFR is not available and thus leverage the large clinical outcomes data for iFR in a new measure that is widely available to all standard coronary pressure wires.

Although this preliminary data is strong, none of these measures where made prospectively in actual patients and the iFR was measured off simulated benchtop pressure waveform modeling. This study aims to perform a real-time correlation and agreement between iFR and DFR in patients with moderate coronary stenoses and indications for physiologic assessment.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Moderate Coronary lesion deemed to need iFR assessment - Angiographic severity of 40-70% that operator feels needs physiologic assessment
  • Age 18-90 year old
  • Single worst lesion per patient- Patients may have more than one lesion assessed but only 1 lesion will be evaluated per patient in this study

排除标准

  • STEMI- Angiographic severity of 40-70% that operator feels needs physiologic assessment in setting of STEMI or 48hours within STEMI
  • Atrial fibrillation
  • Inability to provide informed consent- No surrogate or healthcare proxy will be allowed to consent for this study
  • Severe tortuosity- Vessel tortuosity that the operator feels would be difficult to pass 2 pressure wires down or where pseudo lesions may be formed.
  • Saphenous Vein Graft Lesion

结局指标

主要结局

Agreement for treatment with iFR

时间窗: after all subjects are enrolled the RedCap data will be evaluated

. how many patients would be treated differently using iFR vs. DFR

Correlation of iFR and DFR

时间窗: The correlation between values will be the primary endpoint measured and occurs only during the index procedure.

. DFR will be correlated, in VIVO, with the gold standard, diastolic coronary blood flow measurement, the instantaneous wave free ratio (iFR). Both DFR and iFR will be correlated simultaneously during the index procedure in patients with moderate coronary stenoses whom hemodynamic assessment was clinically indicated.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

进行中(未招募)
不适用
A Phase 3, 24-Week, Multi-Center, Open-Label, Randomized, Controlled Trial Comparing the Efficacy and Safety of Prandial Inhalation of Technosphere®/Insulin in Combination with Metformin or Technosphere®/Insulin Alone Versus 2 Oral Anti-Diabetic Agents (Metformin and a Secretagogue) in Subjects With Type 2 Diabetes Mellitus Sub-Optimally Controlled on Combination Metformin and a SecretagogueDiabetes mellitus type IIMedDRA version: 8.1Level: LLTClassification code 10012601Term: Diabetes mellitus
EUCTR2006-002245-36-CZMannKind Corporation525
招募中
3 期
A Phase 3, Multicenter, Open-Label 156-Week Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants with Chronic or Episodic MigraineHeadache10019231Migraine
NL-OMON54251AbbVie Deutschland GmbH & Co. KG5
进行中(未招募)
1 期
Phase 3 Open label clinical trial with oral Atogepant for the prevention of migraineChronic or Episodic Migraine (Migraine without aura, migraine with aura, or chronic migraine)MedDRA version: 22.0Level: LLTClassification code: 10082019Term: Episodic migraine Class: 10029205MedDRA version: 20.0Level: HLTClassification code: 10027603Term: Migraine headaches Class: 10029205MedDRA version: 20.0Level: PTClassification code: 10052787Term: Migraine without aura Class: 100000004852MedDRA version: 20.0Level: PTClassification code: 10027607Term: Migraine with aura Class: 100000004852MedDRA version: 21.1Level: LLTClassification code: 10066636Term: Chronic migraine Class: 10029205MedDRA version: 20.0Level: PTClassification code: 10027599Term: Migraine Class: 100000004852
CTIS2023-507096-21-00AbbVie Deutschland GmbH & Co. KG596
进行中(未招募)
不适用
Evaluate the Safety and Efficacy of Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean Fever (FMF)
EUCTR2015-003522-13-Outside-EU/EEAovartis Pharmaceuticals15
招募中
1 期
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn’s Disease (VIVID-2)Crohn’s Disease
CTIS2022-502841-91-00Eli Lilly & Co.780